Breakthrough Research Unit

Publications (23)

• Article: Antiaromatase agents: preclinical data and neoadjuvant therapy.

  W R Miller, J M Dixon
  Clinical Breast Cancer 10/2000; 1 Suppl 1:S9-14. · 2.38 Impact Factor
• Article: Local endocrine effects of aromatase inhibitors within the breast.

  W R Miller, J M Dixon
  The Journal of Steroid Biochemistry and Molecular Biology 01/2002; 79(1-5):93-102. · 3.05 Impact Factor
• Source

  Available from: mammakarzinom.at

  Article: Anti-tumor effects of letrozole.

  W R Miller, T J Anderson, J M Dixon
  Cancer Investigation 02/2002; 20 Suppl 2:15-21. · 1.85 Impact Factor
• Source

  Available from: Alexey A Larionov

  Article: Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues.

  A A Larionov, L M Berstein, W R Miller
  The Journal of Steroid Biochemistry and Molecular Biology 06/2002; 81(1):57-64. · 3.05 Impact Factor
• Article: Regulatory subunits of PKA and breast cancer.

  W R Miller
  Annals of the New York Academy of Sciences 07/2002; 968:37-48. · 3.15 Impact Factor
• Source

  Available from: Alexey A Larionov

  Article: Aromatase in skeletal muscle.

  A A Larionov, D A Vasyliev, J I Mason, A F Howie, L M Berstein, W R Miller
  The Journal of Steroid Biochemistry and Molecular Biology 04/2003; 84(4):485-92. · 3.05 Impact Factor
• Article: An integrated view of aromatase and its inhibition.

  W R Miller, T J Anderson, D B Evans, A Krause, G Hampton, J M Dixon
  The Journal of Steroid Biochemistry and Molecular Biology 10/2003; 86(3-5):413-21. · 3.05 Impact Factor
• Article: Biological rationale for endocrine therapy in breast cancer.

  W R Miller
  Bailli&egrave re s Best Practice and Research in Clinical Endocrinology and Metabolism 04/2004; 18(1):1-32. · 4.12 Impact Factor
• Source

  Available from: Philippa T K Saunders

  Article: Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.

  W R Miller, T J Anderson, J M Dixon, P T K Saunders
  British Journal of Cancer 06/2006; 94(9):1333-8. · 5.04 Impact Factor
• Article: Aromatase and the breast: regulation and clinical aspects.

  W R Miller
  Maturitas 08/2006; 54(4):335-41. · 2.77 Impact Factor
• Article: Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors.

  Mr J Michael Dixon
  Women s Health 05/2008; 4(3):229-31.
• Source

  Available from: ed.ac.uk

  Article: How can systems pathology help us personalize cancer therapy?

  Dana Faratian, Simon P Langdon, David J Harrison
  Discovery medicine 08/2009; 8(41):81-6.
• Article: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.

  W R Miller
  The Journal of steroid biochemistry and molecular biology 10/2009; 118(4-5):273-6. · 2.66 Impact Factor
• Source

  Available from: Alexey A Larionov

  Article: Challenges in defining predictive markers for response to endocrine therapy in breast cancer.

  Alexey A Larionov, William R Miller
  Future Oncology 11/2009; 5(9):1415-28. · 3.16 Impact Factor
• Source

  Available from: st-andrews.ac.uk

  Article: Cancer systems biology.

  Dana Faratian, James L Bown, V Anne Smith, Simon P Langdon, David J Harrison
  Methods in molecular biology (Clifton, N.J.) 01/2010; 662:245-63.
• Article: Reply to: discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the 'self (stem cell)-seeding' nature of breast cancer disease?

  D Faratian, S J Aitken, J S Thomas, S P Langdon, D J Harrison
  Annals of Oncology 03/2010; 21(6):1375. · 6.43 Impact Factor
• Article: Treatment of breast infection.

  J Michael Dixon, Lucy R Khan
  BMJ (Clinical research ed.). 01/2011; 342:d396.
• Article: Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.

  J Michael Dixon, Lorna Renshaw, Jonathan Dixon, Jeremy Thomas
  Breast Cancer Research and Treatment 08/2011; 130(3):871-7. · 4.43 Impact Factor
• Source

  Available from: Elad Katz

  Article: Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes.

  Colm E Nestor, Raffaele Ottaviano, James Reddington, Duncan Sproul, Diana Reinhardt, Donncha Dunican, Elad Katz, J Michael Dixon, David J Harrison, Richard R Meehan
  Genome Research 11/2011; 22(3):467-77. · 13.61 Impact Factor
• Source

  Available from: Elad Katz

  Article: Targeting of Rac GTPases blocks the spread of intact human breast cancer.

  Elad Katz, Andrew H Sims, Duncan Sproul, Helen Caldwell, Michael J Dixon, Richard R Meehan, David J Harrison
  Oncotarget 06/2012; 3(6):608-19. · 4.78 Impact Factor
• Source

  Available from: Andrew H Sims

  Article: Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.

  Arran K Turnbull, Robert R Kitchen, Alexey A Larionov, Lorna Renshaw, J Michael Dixon, Andrew H Sims
  BMC Medical Genomics 08/2012; 5:35. · 3.69 Impact Factor
• Article: Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns.

  Duncan Sproul, Robert R Kitchen, Colm E Nestor, J Michael Dixon, Andrew H Sims, David J Harrison, Bernard H Ramsahoye, Richard R Meehan
  Genome biology 10/2012; 13(10):R84. · 6.63 Impact Factor
• Source

  Available from: Andrew H Sims

  Article: Transcript and protein profiling identify signaling, growth arrest, apoptosis and NFκB-survival signatures following GnRH receptor activation.

  Colette Meyer, Andrew H Sims, Kevin Morgan, Beth Harrison, Morwenna Muir, Jianing Bai, Dana Faratian, Robert Peter Millar, Simon Langdon
  Endocrine Related Cancer 11/2012; · 4.36 Impact Factor